133 results
Page 2 of 7
8-K
db3m e28bf
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.1
dc0gelokpt752
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.1
e2s759ix6shk6 g0io
5 Feb 24
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for AmeluzĀ® to Permit Up to Three Tubes per Use
5:25pm
8-K
EX-10.1
766r1bf
2 Feb 24
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-99.1
dq9bx2chbqm55ly
11 Jan 24
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
4:40pm
8-K
EX-10.1
eaua64p5zr9u508ch f7
15 Dec 23
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-99.1
fhy4xnphqm4d 9yl9
9 Nov 23
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
5:15pm
8-K
EX-10.2
4zedmnzjq6cvqn3ub7
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
8-K
EX-10.1
u5ql9c0zbyg6it59s
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
8-K
EX-99.1
pnkjjovus2fv7ehd50te
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
8-K
xmrpcfakbgn 5wvo
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
424B4
9tloarezn344w 7kl
1 Nov 23
Prospectus supplement with pricing info
5:09pm